Delayed
Hong Kong S.E.
11:29:36 2024-06-04 pm EDT
|
5-day change
|
1st Jan Change
|
18.56
HKD
|
+0.43%
|
|
+1.31%
|
+33.33%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
4,755
|
4,996
|
7,703
|
10,383
|
-
|
Enterprise Value (EV)
1 |
3,795
|
4,177
|
5,927
|
7,788
|
6,872
|
P/E ratio
|
5.3
x
|
6.05
x
|
7.36
x
|
9.68
x
|
9.01
x
|
Yield
|
4.04%
|
4.7%
|
-
|
2.57%
|
-
|
Capitalization / Revenue
|
1.89
x
|
1.82
x
|
2.44
x
|
2.88
x
|
2.54
x
|
EV / Revenue
|
1.51
x
|
1.52
x
|
1.88
x
|
2.16
x
|
1.68
x
|
EV / EBITDA
|
3.39
x
|
3.44
x
|
-
|
5.91
x
|
4.66
x
|
EV / FCF
|
3,706,970
x
|
3,546,040
x
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
-
|
-
|
-
|
Price to Book
|
1.98
x
|
1.7
x
|
2.52
x
|
2.49
x
|
1.93
x
|
Nbr of stocks (in thousands)
|
674,684
|
682,330
|
608,843
|
606,307
|
-
|
Reference price
2 |
7.048
|
7.322
|
12.65
|
17.13
|
17.13
|
Announcement Date
|
3/24/22
|
3/30/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
1,919
|
2,518
|
2,750
|
3,156
|
3,610
|
4,086
|
EBITDA
1 |
-
|
1,121
|
1,213
|
-
|
1,319
|
1,475
|
EBIT
1 |
-
|
1,013
|
1,094
|
1,215
|
1,254
|
1,382
|
Operating Margin
|
-
|
40.22%
|
39.78%
|
38.52%
|
34.72%
|
33.83%
|
Earnings before Tax (EBT)
1 |
-
|
1,026
|
940.1
|
1,217
|
1,285
|
1,417
|
Net income
1 |
-
|
923.4
|
855.4
|
1,122
|
1,150
|
1,233
|
Net margin
|
-
|
36.66%
|
31.11%
|
35.55%
|
31.85%
|
30.17%
|
EPS
2 |
1.350
|
1.330
|
1.210
|
1.720
|
1.770
|
1.900
|
Free Cash Flow
|
-
|
1,024
|
1,178
|
-
|
-
|
-
|
FCF margin
|
-
|
40.65%
|
42.83%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
91.34%
|
97.12%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
110.87%
|
137.7%
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
0.2849
|
0.3440
|
-
|
0.4400
|
-
|
Announcement Date
|
3/25/21
|
3/24/22
|
3/30/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
960
|
819
|
1,776
|
2,595
|
3,511
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
1,024
|
1,178
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
70.2%
|
32.2%
|
35.9%
|
29.7%
|
24.1%
|
ROA (Net income/ Total Assets)
|
-
|
26.6%
|
20.4%
|
27%
|
25.3%
|
-
|
Assets
1 |
-
|
3,473
|
4,192
|
4,160
|
4,545
|
-
|
Book Value Per Share
2 |
-
|
3.560
|
4.310
|
5.020
|
6.880
|
8.860
|
Cash Flow per Share
2 |
-
|
1.480
|
1.670
|
2.160
|
1.710
|
-
|
Capex
1 |
-
|
5.7
|
5.77
|
-
|
185
|
-
|
Capex / Sales
|
-
|
0.23%
|
0.21%
|
-
|
5.12%
|
-
|
Announcement Date
|
3/25/21
|
3/24/22
|
3/30/23
|
3/28/24
|
-
|
-
|
Last Close Price
17.13
CNY Average target price
16.5
CNY Spread / Average Target -3.67% Consensus |
1st Jan change
|
Capi.
|
---|
| +33.33% | 1.43B | | -0.38% | 90.85B | | -0.92% | 39.02B | | -9.57% | 33.46B | | -17.98% | 14.51B | | -6.74% | 13.22B | | -9.76% | 11.65B | | -47.31% | 10.57B | | +6.52% | 9.23B | | +137.06% | 7.71B |
Biopharmaceuticals
|